Benchmarking Antimicrobial Drug Use: Opportunities and Challenges
- PMID: 38960741
- PMCID: PMC11224038
- DOI: 10.3947/ic.2024.0063
Benchmarking Antimicrobial Drug Use: Opportunities and Challenges
Conflict of interest statement
HBK is editorial board of Infect Chemother; however, he did not involve in the peer reviewer selection, evaluation, and decision process of this article. Otherwise, no potential conflicts of interest relevant to this article was reported.
Comment on
-
Nationwide Analysis of Antimicrobial Prescription in Korean Hospitals between 2018 and 2021: The 2023 KONAS Report.Infect Chemother. 2024 Jun;56(2):256-265. doi: 10.3947/ic.2024.0013. Infect Chemother. 2024. PMID: 38960739 Free PMC article.
References
-
- World Health Organization (WHO) Comprehensive review of the WHO global action plan on antimicrobial resistance: evaluation brief – September 2021. [Accessed 13 June 2024]. Available at: https://www.who.int/publications/m/item/comprehensive-review-of-the-who-....
-
- Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:e51–e77. - PMC - PubMed
